Compass Therapeutics (CMPX) announced the first patient has been dosed in an Investigator Sponsored Trial, IST, to evaluate tovecimig for the first time in the front-line setting for patients with biliary tract cancer. The IST is being conducted at The University of Texas MD Anderson Cancer Center. “This first-line study of tovecimig in patients with BTC represents a significant step forward and we are deeply grateful to the dedicated team at MD Anderson for their leadership in conducting this trial,” said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. “The IST complements our ongoing second-line Phase 2/3 study of tovecimig in patients with biliary tract cancer; importantly, we recently announced that tovecimig met the primary endpoint in our Phase 2/3 Study. We expect to report results of the secondary endpoints in the Phase 2/3 Study, including progression-free survival and overall survival, in the fourth quarter of this year.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Biotech Alert: Searches spiking for these stocks today
- Compass Therapeutics price target raised to $24 from $10 at H.C. Wainwright
- Compass Therapeutics upgraded to Outperform from Market Perform at Leerink
- Positive Buy Rating for Tovecimig-Paclitaxel Combo Following Promising COMPANION-002 Trial Results
- Compass Therapeutics price target raised to $11 from $10 at Stifel
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue